ResMed Inc (ASX: RMD) is a United States based business that develops and manufactures medical devices to help people with sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed, which is short for Respiratory Medicine, was founded in 1989 by Dr Peter Farrell and now helps customers & patients in over 120 countries.
Here are my three key investor takeaways from a shortened week that saw the S&P/ASX 200 (ASX: XJO) finish broadly flat.
The S&P/ASX 200 (ASX:XJO) finished flat on Wednesday as Ramsay Health Care (ASX:RHC) and Rio Tinto (ASX:RIO) shares were in the news.
It was another weak day for the S&P/ASX 200 (ASX: XJO) on Tuesday as Pendal (ASX:PDL) and Iress (ASX:IRE) shares made headlines.
Cathie Wood’s ARK Genomic Revolution ETF (BATS: ARKG) and ASX-listed biotech stocks have been beaten up mercilessly, so is now the time to buy?
The Cochlear Limited (ASX: COH) share price has bounced this morning after recording a 28% jump in profit for the first half of FY22.
Australian investors had some respite on Friday, as volatility disappeared and the S&P/ASX 200 (ASX: XJO) gained 2.2% to finish the week.
Homegrown medical device company Resmed Inc (ASX: RMD) has updated the market with its Q2 results, boosting profit 12% year on year.
The S&P/ASX 200 (ASX:XJO) finished the week and the month on a negative note as Macquarie (ASX:MQG) and Vulcan (ASX:VUL) shares made headlines.
The Resmed CDI (ASX: RMD) share price has launched into the green this morning after the business delivered its first quarter update.
